MedTrace Logo

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment

NCT00909129 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2009-05-27

No results posted yet for this study

Summary

The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response. Furthermore, to study Interferon-inducible protein-10 (IP-10) dynamics during HCV treatment, and correlate this to treatment outcome.

Conditions

  • Human Immunodeficiency Virus
  • Chronic Hepatitis C

Interventions

DRUG

pegylated interferon-alpha (Pegasys)

Pegylated interferon-alpha 2a 180 micrograms s.c. weekly

DRUG

ribavirin (COPEGUS)

ribavirin bid 800-1200 mg depending on HCV genotype and body weight

Sponsors & Collaborators

Principal Investigators

  • Annette Alaeus, MD;PhD · Infectious Diseases Unit, Dept of Medicine Solna, Karolinska Institutet Stockholm

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00909129 on ClinicalTrials.gov